OncoTargets and Therapy (Nov 2019)
Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
Abstract
James A Radosevich, Michael Babich LabyRx Immunologic Therapeutics (USA) Limited, Sacramento, California, USACorrespondence: James A Radosevich 1009 Johnson Ct, Belvidere, IL 61008 Tel +1 530 330 5888Email [email protected]: A paradigm shift is currently underway on the relationship between cancer treatment markers and therapies. Labyrinthin is a prime example of such a marker because it is a pan-cancer target for adenocarcinomas. This movement supports the idea that we must change our thinking from various cancer types (eg, lung, breast, colon) to “cancer arising” in a given tissue or organ. In doing so, this would further support the efforts toward pan-treatments rather than organ-specific treatments.Keywords: labyrinthin, MCA 44-3A6 antibody, cancer marker, cancer target, pan-cancer, pan-tumor, biomarkers, cancer diagnosis, adenocarcinoma
